홈
탐색
nav.journalClub
트렌드
더보기
synapse
⌘+K
언어
한국어
Oligometastatic prostate cancer: time to integrate metastasis-directed therapy | Synapse
March 3, 2026
Oligometastatic prostate cancer: time to integrate metastasis-directed therapy
SS
Simon K B Spohn
PG
Prof Anca-Ligia Grosu
University of Freiburg
Key Points
Oligometastatic prostate cancer treatment shows promising outcomes when using metastasis-directed therapy, emphasizing its potential benefits.
Patients treated with metastasis-directed therapy experienced significant improvements in cancer progression rates, particularly in early-stage cases.
Observational analysis reveals that integrating metastasis-directed therapy into existing treatment protocols could enhance overall patient care.
This highlights the need for further trials to validate these findings and explore long-term effects on patient survival.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Spohn et al. (Sun,) studied this question.
synapsesocial.com/papers/69a765d9badf0bb9e87daaff
https://doi.org/https://doi.org/10.1016/s1470-2045(25)00760-0